Skip to main content
Premium Trial:

Request an Annual Quote

Geneoscopy Submits PMA Application to FDA for Stool-Based Colorectal Cancer Screening Test

NEW YORK – Diagnostics firm Geneoscopy said Tuesday that it has submitted a premarket approval application to the US Food and Drug Administration for its stool-based screening test to detect colorectal cancer and advanced adenomas in average-risk individuals.

The PMA bid is supported by data from a trial called CRC-PREVENT, in which the firm's RNA-based assay demonstrated 94 percent sensitivity for CRC and 45 percent sensitivity for advanced adenomas, a precursor lesion typically removed when identified during a colonoscopy.

In a subset of subjects aged 45 to 49, the test showed 100 percent sensitivity for CRC and 44 percent sensitivity for advanced adenomas at 89 percent specificity.

"Despite CRC being the second leading cause of cancer death in the US, millions of eligible Americans do not get screened — many due to a lack of knowledge of the importance of screening, lack of access to screening, and concerns about the invasive nature of options like colonoscopy," Geneoscopy CSO Erica Barnell said in a statement. "We are committed to closing this gap."

According to the company, the CRC-PREVENT results meet or exceed the sensitivity profiles reported for other noninvasive CRC screening tests in a prospective setting. As such, the company believes it will be successful in seeing its test approved by the FDA. The agency named the assay a breakthrough device in 2021, a designation that can confer a speedier review process.

Moving forward, Geneoscopy CEO Andrew Barnell said the company's stool RNA platform may yield additional tests, including more precise CRC screening assays and "high-value diagnostic testing for other gastrointestinal indications."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.